These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 30585839)

  • 41. HIV providers' likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report.
    Adams LM; Balderson BH
    AIDS Care; 2016 Sep; 28(9):1154-8. PubMed ID: 26915281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pre-exposure prophylaxis (PrEP) for people who inject drugs: reconciling community views and biomedical advances.
    Guise A; Albers ER; Strathdee SA
    Addiction; 2017 Apr; 112(4):584-585. PubMed ID: 28181334
    [No Abstract]   [Full Text] [Related]  

  • 43. HIV Infection and Drug Resistance with Unsupervised Use of HIV Pre-Exposure Prophylaxis.
    Volk JE; Nguyen DP; Hare CB; Marcus JL
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):329-330. PubMed ID: 29262689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV.
    Auerbach JD; Hoppe TA
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19983. PubMed ID: 26198346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians.
    Blackstock OJ; Moore BA; Berkenblit GV; Calabrese SK; Cunningham CO; Fiellin DA; Patel VV; Phillips KA; Tetrault JM; Shah M; Edelman EJ
    J Gen Intern Med; 2017 Jan; 32(1):62-70. PubMed ID: 27778215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preventing HIV Infection in High-Risk Adolescents Using Preexposure Prophylaxis (PrEP).
    Blackwell CW
    J Assoc Nurses AIDS Care; 2018; 29(5):770-774. PubMed ID: 30146018
    [No Abstract]   [Full Text] [Related]  

  • 48. Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties.
    Sanchez Conde M; Vivancos Gallego MJ; Moreno Guillen S
    Farm Hosp; 2017 Sep; 41(5):630-637. PubMed ID: 28847253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?
    Wong NS; Kwan TH; Tsang OTY; Lee MP; Yam WC; Lam W; Leung WS; Chan JMC; Ho KM; Lee SS
    Sci Rep; 2018 Aug; 8(1):11641. PubMed ID: 30076362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Pre-Exposure Prophylaxis-Stigma Paradox: Learning from Canada's First Wave of PrEP Users.
    Grace D; Jollimore J; MacPherson P; Strang MJP; Tan DHS
    AIDS Patient Care STDS; 2018 Jan; 32(1):24-30. PubMed ID: 29185801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interest in HIV pre-exposure prophylaxis in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France).
    Coulaud PJ; Sagaon-Teyssier L; M'madi Mrenda B; Maradan G; Mora M; Bourrelly M; Dembélé Keita B; Keita AA; Anoma C; Babo Yoro SA; Dah TTE; Coulibaly C; Mensah E; Agbomadji S; Bernier A; Couderc C; Laurent C; Spire B;
    Trop Med Int Health; 2018 Oct; 23(10):1084-1091. PubMed ID: 30055043
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Likely impact of pre-exposure prophylaxis on HIV epidemics among men who have sex with men.
    Zablotska IB
    Sex Health; 2017 Feb; 14(1):97-105. PubMed ID: 27883309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-acting injectable ART for HIV: a (cautious) step forward.
    Venkatesan P
    Lancet Microbe; 2022 Feb; 3(2):e94. PubMed ID: 35544049
    [No Abstract]   [Full Text] [Related]  

  • 54. Long-acting cabotegravir for prevention: hope versus reality.
    McCormack S; Boffito M
    Lancet HIV; 2017 Aug; 4(8):e322-e323. PubMed ID: 28546089
    [No Abstract]   [Full Text] [Related]  

  • 55. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
    J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One step closer to ultra-long-acting PREP?
    Harper KN
    AIDS; 2019 Mar; 33(3):N2. PubMed ID: 30585839
    [No Abstract]   [Full Text] [Related]  

  • 57. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
    Meyers K; Rodriguez K; Moeller RW; Gratch I; Markowitz M; Halkitis PN
    PLoS One; 2014; 9(12):e114700. PubMed ID: 25502768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
    John SA; Whitfield THF; Rendina HJ; Parsons JT; Grov C
    AIDS Behav; 2018 Apr; 22(4):1184-1189. PubMed ID: 28913659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.